Literature DB >> 24652235

Resveratrol and the eye: activity and molecular mechanisms.

Christina Bola1, Hannah Bartlett, Frank Eperjesi.   

Abstract

PURPOSE: Alcohol consumption is inversely correlated with the incidence of cardiovascular disease. It is thought that red wine is specifically responsible for these cardiovascular benefits, due to its ability to reduce vascular inflammation, facilitate vasorelaxation, and inhibit angiogenesis. This is because of its high polyphenolic content. Resveratrol is the main biologically active polyphenol within red wine. Owing to its vascular-enhancing properties, resveratrol may be effective in the microcirculation of the eye, thereby helping prevent ocular diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma. Such conditions are accountable for worldwide prevalence of visual loss.
METHOD: A review of the relevant literature was conducted on the ScienceDirect, Web of Science, and PubMed databases. Key words used to carry out the searches included 'red wine', 'polyphenols', 'resveratrol', 'eye' and 'ocular'. Articles relating to the effects of resveratrol on the eye were reviewed.
RESULTS: The protective effects of resveratrol within the eye are extensive. It has been demonstrated to have anti-oxidant, anti-apoptotic, anti-tumourogenic, anti-inflammatory, anti-angiogenic and vasorelaxant properties. There are potential benefits of resveratrol supplementation across a wide range of ocular diseases. The molecular mechanisms underlying these protective actions are diverse.
CONCLUSION: Evidence suggests that resveratrol may have potential in the treatment of several ocular diseases. However, while there are many studies indicating plausible biological mechanisms using animal models and in-vitro retinal cells there is a paucity of human research. The evidence base for the use of resveratrol in the management of ocular diseases needs to be increased before recommendations can be made for the use of resveratrol as an ocular supplement.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24652235     DOI: 10.1007/s00417-014-2604-8

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  95 in total

Review 1.  Wine phenolics.

Authors:  Andrew L Waterhouse
Journal:  Ann N Y Acad Sci       Date:  2002-05       Impact factor: 5.691

2.  Effects of high glucose concentration on the barrier function and the expression of tight junction proteins in human retinal pigment epithelial cells.

Authors:  Marta Villarroel; Marta García-Ramírez; Lidia Corraliza; Cristina Hernández; Rafael Simó
Journal:  Exp Eye Res       Date:  2009-08-04       Impact factor: 3.467

3.  SIRT1 promotes RGC survival and delays loss of function following optic nerve crush.

Authors:  Ling Zuo; Reas S Khan; Vivian Lee; Kimberly Dine; Wen Wu; Kenneth S Shindler
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-26       Impact factor: 4.799

4.  Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures.

Authors:  B Szende; E Tyihák; Z Király-Véghely
Journal:  Exp Mol Med       Date:  2000-06-30       Impact factor: 8.718

Review 5.  The role of oxidative stress in the pathogenesis of age-related macular degeneration.

Authors:  S Beatty; H Koh; M Phil; D Henson; M Boulton
Journal:  Surv Ophthalmol       Date:  2000 Sep-Oct       Impact factor: 6.048

6.  Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.

Authors:  Konrad T Howitz; Kevin J Bitterman; Haim Y Cohen; Dudley W Lamming; Siva Lavu; Jason G Wood; Robert E Zipkin; Phuong Chung; Anne Kisielewski; Li-Li Zhang; Brandy Scherer; David A Sinclair
Journal:  Nature       Date:  2003-08-24       Impact factor: 49.962

7.  Resveratrol prevents the expression of glaucoma markers induced by chronic oxidative stress in trabecular meshwork cells.

Authors:  Coralia Luna; Guorong Li; Paloma B Liton; Jianming Qiu; David L Epstein; Pratap Challa; Pedro Gonzalez
Journal:  Food Chem Toxicol       Date:  2008-11-06       Impact factor: 6.023

8.  Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD.

Authors:  S V Culpitt; D F Rogers; P S Fenwick; P Shah; C De Matos; R E K Russell; P J Barnes; L E Donnelly
Journal:  Thorax       Date:  2003-11       Impact factor: 9.139

9.  Resveratrol neuroprotection in a chronic mouse model of multiple sclerosis.

Authors:  Zoe Fonseca-Kelly; Mayssa Nassrallah; Jorge Uribe; Reas S Khan; Kimberly Dine; Mahasweta Dutt; Kenneth S Shindler
Journal:  Front Neurol       Date:  2012-05-24       Impact factor: 4.003

10.  The neuroprotective effect of resveratrol on retinal ganglion cells after optic nerve transection.

Authors:  Seok Hwan Kim; Joo Hyun Park; Yu Jeong Kim; Ki Ho Park
Journal:  Mol Vis       Date:  2013-07-25       Impact factor: 2.367

View more
  25 in total

1.  SIRT1 mediated inhibition of VEGF/VEGFR2 signaling by Resveratrol and its relevance to choroidal neovascularization.

Authors:  Huiming Zhang; Shikun He; Christine Spee; Keijiro Ishikawa; David R Hinton
Journal:  Cytokine       Date:  2015-07-11       Impact factor: 3.861

2.  Resveratrol prevents hypoxia-induced retinal ganglion cell death related with ErbB2.

Authors:  Hyemin Seong; Joo Yeon Jeong; Jinhyun Ryu; Juyeong Park; Yong-Seop Han; Hyun-Kyung Cho; Seong Jae Kim; Jong Moon Park; Sang Soo Kang; Seong Wook Seo
Journal:  Int J Ophthalmol       Date:  2022-03-18       Impact factor: 1.779

3.  Toxic effects of A2E in human ARPE-19 cells were prevented by resveratrol: a potential nutritional bioactive for age-related macular degeneration treatment.

Authors:  Agustina Alaimo; Mariana Carolina Di Santo; Ana Paula Domínguez Rubio; Gabriela Chaufan; Guadalupe García Liñares; Oscar Edgardo Pérez
Journal:  Arch Toxicol       Date:  2019-12-02       Impact factor: 5.153

4.  RES-loaded pegylated CS NPs: for efficient ocular delivery.

Authors:  Saravanakumar Pandian; Vinoth Jeevanesan; Chandrasekar Ponnusamy; Subramanian Natesan
Journal:  IET Nanobiotechnol       Date:  2017-02       Impact factor: 1.847

5.  Resveratrol based oral nutritional supplement produces long-term beneficial effects on structure and visual function in human patients.

Authors:  Stuart Richer; Shana Patel; Shivani Sockanathan; Lawrence J Ulanski; Luke Miller; Carla Podella
Journal:  Nutrients       Date:  2014-10-17       Impact factor: 5.717

6.  Dietary Compound Chrysin Inhibits Retinal Neovascularization with Abnormal Capillaries in db/db Mice.

Authors:  Min-Kyung Kang; Sin-Hye Park; Yun-Ho Kim; Eun-Jung Lee; Lucia Dwi Antika; Dong Yeon Kim; Yean-Jung Choi; Young-Hee Kang
Journal:  Nutrients       Date:  2016-12-03       Impact factor: 5.717

7.  Tissue Distribution of trans-Resveratrol and Its Metabolites after Oral Administration in Human Eyes.

Authors:  Shuaishuai Wang; Zheng Wang; Shuo Yang; Tiemei Yin; Yaoli Zhang; Yuanjun Qin; Robert N Weinreb; Xufang Sun
Journal:  J Ophthalmol       Date:  2017-03-20       Impact factor: 1.909

8.  Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells.

Authors:  Murali Subramani; Murugeswari Ponnalagu; Lekshmi Krishna; Nallathambi Jeyabalan; Priyanka Chevour; Anupam Sharma; Chaitra Jayadev; Rohit Shetty; Nargis Begum; Govindaraju Archunan; Debashish Das
Journal:  Sci Rep       Date:  2017-09-25       Impact factor: 4.379

9.  Resveratrol inhibits epithelial-mesenchymal transition of retinal pigment epithelium and development of proliferative vitreoretinopathy.

Authors:  Keijiro Ishikawa; Shikun He; Hiroto Terasaki; Hossein Nazari; Huiming Zhang; Christine Spee; Ram Kannan; David R Hinton
Journal:  Sci Rep       Date:  2015-11-10       Impact factor: 4.379

Review 10.  Age-Related Macular Degeneration: New Paradigms for Treatment and Management of AMD.

Authors:  Luis Fernando Hernández-Zimbrón; Ruben Zamora-Alvarado; Lenin Ochoa-De la Paz; Raul Velez-Montoya; Edgar Zenteno; Rosario Gulias-Cañizo; Hugo Quiroz-Mercado; Roberto Gonzalez-Salinas
Journal:  Oxid Med Cell Longev       Date:  2018-02-01       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.